28,000 Shares in Dynavax Technologies Co. (NASDAQ:DVAX) Purchased by KLP Kapitalforvaltning AS

KLP Kapitalforvaltning AS acquired a new position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 28,000 shares of the biopharmaceutical company's stock, valued at approximately $358,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC increased its stake in shares of Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 2,034 shares during the last quarter. GAMMA Investing LLC increased its position in Dynavax Technologies by 55.1% during the fourth quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock worth $52,000 after buying an additional 1,457 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Dynavax Technologies during the fourth quarter valued at about $71,000. Nisa Investment Advisors LLC lifted its position in shares of Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after buying an additional 1,076 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Dynavax Technologies in the third quarter worth about $89,000. Institutional investors own 96.96% of the company's stock.

Analyst Upgrades and Downgrades

DVAX has been the topic of a number of recent analyst reports. The Goldman Sachs Group downgraded Dynavax Technologies from a "neutral" rating to a "sell" rating and cut their price objective for the company from $15.00 to $12.00 in a research note on Tuesday, February 11th. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st. HC Wainwright reaffirmed a "buy" rating and set a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, StockNews.com upgraded shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th.

Dynavax Technologies Stock Performance

DVAX traded down $1.06 during midday trading on Thursday, reaching $10.97. The company's stock had a trading volume of 4,842,373 shares, compared to its average volume of 2,206,126. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The company has a fifty day simple moving average of $13.24 and a 200 day simple moving average of $12.57. The stock has a market cap of $1.36 billion, a P/E ratio of 60.94 and a beta of 1.26. Dynavax Technologies Co. has a twelve month low of $9.74 and a twelve month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.05. The business had revenue of $72.03 million for the quarter, compared to the consensus estimate of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. Research analysts expect that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.